$6.69+0.24 (+3.72%)
Upstream Bio, Inc., a clinical-stage biotechnology company, develops treatments for inflammatory diseases focusing on severe respiratory disorders.
Upstream Bio, Inc. in the Healthcare sector is trading at $6.69. Wall Street consensus targets $41.62 (8 analysts), implying a +522.2% move over the next 12 months. The stock is currently near its 52-week low of $6.41, remaining 62.8% below its 200-day moving average. On fundamentals, Piotroski 4/9 shows mixed financial quality, Altman Z in the distress zone. Risk note: MACD remains below its signal line. The Whystock Score of 50/100 suggests a balanced risk-reward profile.
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Upstream Bio, Inc., a clinical-stage biotechnology company, develops treatments for inflammatory diseases focusing on severe respiratory disorders. It offers verekitug, which is in Phase 2 trials for the treatment of severe asthma and chronic rhinosi...
Upstream Bio, Inc. (UPB) delivered earnings and revenue surprises of +5.96% and +102.75%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Wix downgraded, TripAdvisor upgraded: Wall Street's top analyst calls
Pre-Market Stock Futures: Futures are trading lower as we prepare to end another up-and-down week, and, as we mentioned before, it all depends on the status of the war with Iran and the price of oil on any given day. Those two items have dictated the direction of stocks, bonds, precious metals, and crypto since ... Here Are Friday’s Top Wall Street Analyst Research Calls: Brown-Forman, Chord Energy, Emerson Electric, FuboTV, Genmab, Honeywell, Knight-Swift, Wix.Com, and More
Upstream Bio (NASDAQ:UPB) reported top-line results from its Phase II VALIANT trial evaluating verekitug in adults with severe asthma, highlighting statistically significant reductions in annualized asthma exacerbation rate (AAER) with multiple dosing regimens and a safety profile the company said w
We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...